biotech Β· Essential Tremor Β· Systemic Lupus Erythematosus
Chongqing Precision Biotech
Chongqing Precision Biotech Co., Ltd
Chongqing Precision Biotech trial registry β 125 ClinicalTrials.gov studies with program phase, status, and indication context.
ιεΊεΈεδΈε€§ιι«η§εδΈεAζ , Chongqing, CN HQ
2016 Founded
5 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- ιεΊεΈεδΈε€§ιι«η§εδΈεAζ , Chongqing, CN
- Founded
- 2016
- Employees
- 5
- Programs
- 109
- Drugs
- 57
- Patents
- 158
Chongqing Precision Biotech clinical trials
Registry index of 125 ClinicalTrials.gov studies linked to Chongqing Precision Biotech programs β each row shows trial ID, program name, phase, status, and indication.
Chongqing Precision Biotech trial registry β 125 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Chongqing Precision Biotech.
-
PRAX-628-323 β Phase 3
Clinical update -
PRAX-628-322 β Phase 3
Clinical update -
PRAX-628-102 β Phase 1
Clinical update -
PBGENE-HBV-01 β Phase 1
Clinical update -
PB-2018-V12 β Phase 1
Clinical update -
PRAX-114-231 β Phase 2
Clinical update -
Salkera Emollient Foam β Approved
Clinical update -
pCAR-19B cells β Phase 1
Clinical update
Trial registry
-
CTIS β -
CTIS β - 2024-515598-82-00CTIS β
PRAX-222
Voltage-gated sodium channel type II alpha subunit (SCN2A) developmental and epileptic encephalopathy (DEE)
-
CTIS β -
CTIS β -
CTIS β -
CTIS β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β - NCT06999902CT.gov β
20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks
Focal Seizure
-
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β -
CT.gov β